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Abstract
Background: Genetic testing is becoming an essential tool for breast cancer (BC) diagnosis and treatment pathway,
and particularly important for early detection and cancer prevention. The purpose of this study was to explore the
diagnostic yield of targeted sequencing of the high priority BC genes.
Methods: We have utilized a cost-effective targeted sequencing approach of high priority actionable BC genes
(BRCA1, BRCA2, ERBB2 and TP53) in a homogeneous patient cohort from Bangladesh (n = 52) by using tumor and
blood samples.
Results: Blood derived targeted sequencing revealed 25.58% (11/43) clinically relevant mutations (both pathogenic
and variants of uncertain significance (VUS)), with 13.95% (6/43) of samples carrying a pathogenic mutations. We
have identified and validated five novel pathogenic germline mutations in this cohort, comprising of two frameshift
deletions in BRCA2, and missense mutations in BRCA1, BRCA2 and ERBB2 gene respectively. Furthermore, we have
identified three pathogenic mutations and a VUS within three tumor samples, including a sample carrying pathogenic
mutations impacting both TP53 (c.322dupG; a novel frameshift insertion) and BRCA1 genes (c.116G > A). 22% of tissue
samples had a clinically relevant TP53 mutation. Although the cohort is small, we have found pathogenic mutations to
be enriched in BRCA2 (9.30%, 4/43) compare to BRCA1 (4.65%, 2/43). The frequency of germline VUS mutations found
to be similar in both BRCA1 (4.65%; 2/43) and BRCA2 (4.65%; 2/43) compared to ERBB2 (2.32%; 1/43).
Conclusions: This is the first genetic study of BC predisposition genes in this population, implies that genetic
screening through targeted sequencing can detect clinically significant and actionable BC-relevant mutations.
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Background
Breast cancer (BC) is the most common type of cancer
among women, impacting 2 million new cases and causes
over 600,000 deaths worldwide [1]. While the prevalence
of BC is increasing globally, it is critical to screen known
BC genes to improve breast cancer survival and early de-
tection, especially in developing countries where majority
of women with BC are diagnosed at an advanced stage.
The five-year survival rate is below 40% in low-income
countries, 60% in middle-income countries and 80% or
over in North America, Sweden and Japan where early de-
tection and different treatment options are available [2].
Traditionally, breast self-examination, clinical breast
assessment and mammography all have been used alone
or in combination to screen BC and facilitate early de-
tection of potentially malignant breast lesions. In recent
years, genetic screening has become a critical tool for
BC assessment, diagnosis and in guiding treatment
choices [3, 4].Mutation profiling for BC has been an
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integral part of clinical care since the discovery of the
BRCA1 and BRCA2 genes [5–7].Cases with BRCA1 and
BRCA2 pathogenic mutations have a significantly in-
creased risk of developing BC before the age of 50 years
[8–11]. Breast cancer risk for late onset cases (above 70
years old) who carry pathogenic mutation in BRCA1 and
BRCA2 is 57 and 50%, respectively [12]. These numbers
are higher than any other studied mutations associated
with hereditary (familial) BC. Importantly, the frequency
distribution of some of the BRCA mutations varies by
population studied, suggesting a population specific mu-
tational profile.
Another important gene is TP53 that was originally
identified as a risk factor for Li–Fraumeni syndrome.
TP53 mutations are the most frequent genetic abnormal-
ities in BC tumors. Approximately 30% of all BC tumors
reported to have a mutation in TP53 and mutation within
this gene is also associated with poor prognosis [13]. The
mutation frequency varies depending on the tumor sub-
types, with mutations in 26% luminal, 50% in HER2 ampli-
fied tumors, and 88% in basal-like subtypes [13].
It has been reported that theTP53 mutation status may
influence the patient’s response to treatment, and deter-
mine resistance to several chemotherapy drugs [14–16].
Although genetic mutation screening is becoming an
essential test for BC diagnosis and therapeutics, the cost
associated with whole genome sequencing is still high and
not a feasible option for clinical practice in developing
countries. Given these challenges, we explored the diag-
nostic yield of targeted sequencing of the high priority BC
genes BRCA1, BRCA2, TP53 and ERBB2.
Methods
Study subjects
The cohort comprised of 52 individuals (43 blood and 9
breast tissue samples) with age ranges between 30 and
70 years, including 30.77% (16/52, 13 blood and 3 tissue
samples) between 30 and 39 years, 36.54% (19/52, 16
blood and 3 tissue samples) between 40 and 49 years
and 32.69% (17/52, 14 blood and 3 tissue samples) be-
tween 50 and 70 years (Table 3). Of the 52, 76.92% (40/
52, 38 blood and 2 tissue samples) had a positive family
history of breast cancer and 61.53% (32/52, 23 blood and
9 tissue samples) were diagnosed with breast cancer.
30.77% (16/52, all are blood samples) had symptoms of
breast lump, pain and swelling but were, as yet, undiag-
nosed. Although the rest 7.70% (4/52) had no symptoms,
these individuals were included into the cohort due to
positive family history. Of the 32 diagnosed breast can-
cer patients, 15.62% (5/32, all are blood samples) were in
stage I, 53.13% (17/32, 12 blood and 5 tissue samples)
were in stage II, 25% (8/32, 6 blood and 2 tissue sam-
ples) were in stage III and 6.25% (2/32, all are tissue
samples) did not provide stage information. These cases
went through clinical assessment for breast cancer at
multiple centers between January, 2017 to August, 2018
in Dhaka, Bangladesh. They were prospectively recruited
from Dhaka Medical College and Hospital, Holy Family
Red Crescent Medical College and Hospital, Oncology
Center and General Hospital, and IbnSina Diagnostic
and Imaging Center of Bangladesh. The study was ap-
proved by the Institutional Review Board of Holy Family
Red Crescent Medical College, and all samples were col-
lected with written informed consent.
DNA extraction and amplification
DNA was extracted from breast tissue and blood sample
using GeneJET Genomic DNA Purification Kit (Thermo
Fisher Scientific, USA) and ReliaPrep™ Blood gDNA iso-
lation kit (Promega, USA) respectively according to
manufacturer protocols. The concentration and quality
of DNA was measured using NanoPhotometer C40
(Implen, Germany).We have developed a panel com-
prised of four high impact genes in breast cancer using
high throughput sequencing technology. We have de-
signed (using Primer 3 plus software, IDT and UCSC
Genome Browser) 52 sets of primers targeting all exons
and splicing junctions of BRCA1, BRCA2, TP53 and
ERBB2 genes (Additional file 1). In total, 13 sets of
multiplex PCR were carried out to amplify all the 52
amplicons (Additional file 1: Table S1-S5) using GoTaq®
Hot Start Colorless Master Mix and GoTaq Long PCR
Master Mix (Promega, USA). The amplicons were visu-
ally confirmed by 0.8% agarose gel electrophoresis. After
confirmation, amplicons were purified using the Agen-
court AMPure XP PCR purification bead (Beckman
Coulter, Pasadena, CA) and quantified using the Quanti-
Fluor® ONE dsDNA System (Promega, USA). Then 1 ng
target amplicons were used for library preparation. Nex-
tera XT library preparation kit (Illumina, Inc., San Diego,
CA), using the manufacturer’s recommended protocol,
was used for library preparation.
DNA sequencing and analysis
The barcoded libraries were subsequently sequenced at
NeuroGen Technologies Ltd. genetics and genomics la-
boratory using the MiniSeq sequencer (Illumina, Inc.
USA) with miniseq mid output kit, which generated 150
base paired-end sequence reads. The run was set up in
local run manager that is an integrated computer software
platform of MiniSeq, which uses a Burrows-Wheeler
Aligner (BWA) [17] and the Genome Analysis ToolKit
(GATK 4.0.11.0) [18] for converting raw sequence reads
to Binary Alignment/Map (BAM) and Variant Call Format
(VCF) v4.1 files. Sequencing proceeded on the platform
for 24 h with default settings within the MiniSeq system.
For quality control, a Q-score of 30 was used as a thresh-
old for each identified variant, corresponding to a 1:1000
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error rate. The average coverage is 91.42% for all four genes
(for 52 primer sets) and 96% of the amplicons have a mean
sequencing coverage of 50X.We have used ANNOVAR
(2018Apr16 version) for functional annotation of the vari-
ants. For genomic annotations, we have also used Geno-
meArc, a custom genetic annotation tool. Mutation
classification analysis was conducted based on American
College of Medical Genetics (ACMG) guidelines [19].
Sanger sequencing was used to confirm the novel muta-
tions [20].
Sanger sequencing
All novel variants identified using MiniSeq (Illumina, Inc.
USA) were validated by Sanger sequencing. For this pur-
pose, PCR was performed using genomic DNA as a tem-
plate and primer pairs flanking the deleterious variant
sites. We have designed primers (Additional file 1: Table
S6) for this validation using Primer 3 plus software, IDT
and UCSC Genome Browser. The PCR products were
visually confirmed by 2.0% agarose gel electrophoresis.
The products were then purified using the Wizard® SV
Gel and PCR Clean-Up System (Promega, USA) according
to the manufacturer’s instructions. Cycle sequencing was
performed using purified PCR products as template and
BigDye® Terminator v3.1 (Applied Biosystem, USA). Then
sequencing was performed using 3500 DNA Analyzer
(Applied Biosystem, USA). Subsequently Sanger sequen-
cing data were analyzed using Sequence Scanner v2.0 (Ap-
plied Biosystem, USA).
Results
We have used nine tumor samples to sequence four
bonafide BC genes and identified three pathogenic muta-
tions and a VUS within three tumor samples (Table 1,
Table 3 and Additional file 1: Table S7). The first patient
(Table 1), carries a TP53 (c.733 G > A) missense patho-
genic mutation in exon 7 that impacts the DNA binding
domain of TP53 protein. The second patient (Table 1)
carries 2 pathogenic mutations in both BRCA1 (c.116
G > A) and TP53 (c.322dupG) gene. A variant of uncer-
tain significance (VUS) in BRCA2 (c. 2459A > G) was
identified in the third patient (Table 1).
The overall clinical yield from the 43 blood specimens
was 11 clinically relevant (pathogenic or VUS) mutations
(25.58%), including 13.95% (6/43) patients with clinically
pathogenic mutations (Table 2, Table 3 and Additional
file 1: Table S7). Among these 6 variants, 4 are novel
pathogenic germline mutations (Table 2) comprising 2
frameshift deletions in BRCA2 (Table 2), 1 missense mu-
tation impacting BRCA2 (Table 2) and 1 missense muta-
tion impacting BRCA1 (Table 2) gene. Two novel
frameshift sequence variants are c.1301_1308delAAA-
GAAAG in exon 10 and c.351_352delTC in exon 4 of
BRCA2. These mutations truncated the protein at amino
acid positions of 118 and 436. In BRCA2 gene, another
novel missense variant c.6451 G > A, was found in exon
11. Another two novel mutations c.5011 T > C and
c.2272 G > C were found in BRCA1 and ERBB2, respect-
ively (Table 2, Table 3 and Additional file 1: Table S7).
All the novel mutations (c.322dupG, c.351_352delTC,
c.1301_1308delAAAGAAAG, c.5011 T > C, c.6451 G > A
and c.2272 G > C) were further validated by Sanger se-
quencing (Fig. 1).
In this cohort, we have also identified 6 known clinic-
ally relevant variants that include 2 known pathogenic
variants, c.7722 G > A in exon 16 of BRCA2 and c.1058
G > A in exon 10 of BRCA1 (Table 2) and the remaining
4 mutations are missense. Out of 4, 2 are located in exon
10 of BRCA2 gene and 2 are located in exon 10 of
BRCA1 gene (Table 2).
Discussion
Although large scale targeted sequencing has identified
new BC mutations in the developed countries [21], data
on the mutational architecture in low and middle in-
come countries, such as Bangladesh, remains limited
[22]. The recent increase of BC prevalence and the de-
tection of bonafide causal genes imply the exploration of
the genomic landscape of BC in countries such as
Bangladesh to facilitate early diagnosis and screening to
target treatments appropriately. We have designed a tar-
geted gene-sequencing panel for known high-risk breast
cancer genes, namely BRCA1, BRCA2, TP53 and ERBB2,
which was after proper quality control incorporated into
the diagnostic pathway.
The incidence and prevalence of BC in Bangladesh is
mostly unknown due to the lack of population-based can-
cer registries either locally or centrally. In Bangladesh,
Table 1 List of clinically relevant mutations within the BRCA1, BRCA2 and TP53 genes in resected breast tumor tissues in our
Bangladeshi cohort
Sample Id Gene
Name
Coordinate
[position] (hg19)
Mutation Types Significance Exon Nucleotide change Amino acid change
1 TP53 7,577,548 Nonsynonymous pathogenic 7 c.733G > A p.Gly245Ser
2 TP53 7,578,490 frameshift insertion* pathogenic 5 c.322dupG p.Val108Glyfs*
BRCA1 41,267,761 Nonsynonymous pathogenic 3 c.116G > A p.Cys39Tyr
3 BRCA2 32,910,951 Nonsynonymous VUS 11 c.2459A > G p.Asp820Gly
*defines the novel variants in our cohort
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most patients are diagnosed at an advanced stage of the
disease and suffer from worse treatment outcome due to
lack of breast cancer awareness, inadequate access to
healthcare and excessive treatment related cost. Genetic
screening for BRCA1/2 and TP53 genes and identification
of novel mutation and variants serves as key roles for
timely diagnosis, treatment, counseling, follow-up of pa-
tients and management of disease [23]. BRCA1/2 carriers
now can have targeted therapies that apply parp-inhibitor
to facilitate DNA repair process in tumor cell. It was
found that the oral PARP inhibitor olaparib has antitu-
mour activity in those patients who have lost BRCA1 or
BRCA2-associated DNA repair [24]. Similarly, for TP53
mutations multiple targeted therapies shown promising
result to improve the survival rate for TP53 mutation car-
riers [25].
We have identified 25.58% (11/43) germline (blood de-
rived DNA) clinically relevant mutations with familial
cancer history. Results obtained in our cohort corrobor-
ate the previously reported studies that investigated only
BRCA genes within familial patients [26]. Of the 11
germline mutations, we identified 10 sequence variants
in BRCA1 and BRCA2 genes, including 13.95% (6/43)
cases carrying a pathogenic mutation and the frequency
correlate strongly with Cyprus study that reported a
similar clinical yield of 13% for BRCA genes [27]. Des-
pite of small cohort size, we have found germline patho-
genic mutation impact on BRCA2 (9.30%, 4/43) which is
approximately 2-fold higher than BRCA1 (4.65%, 2/43),
suggesting that BRCA2 is frequently mutated or altered
in our cohort. This is also consistent with a Chinese co-
hort where BRCA2 was shown to have a higher preva-
lence compared to BRCA1 [28]. The frequency of
germline VUS mutations are same in both BRCA1
(4.65%; 2/43) and BRCA2 (4.65%; 2/43) compared to
ERBB2 (2.32%; 1/43).
Of the 11germline mutations, we have found 2 novel
pathogenic frameshift deletions (Table 2) in exon 10 and
4 of BRCA2 (Table 2) gene respectively. These mutations
truncated the BRCA2 protein at amino acid positions of
118 and 436. The truncated protein lacks BRCA2 func-
tional domains (RAD51 and a DNA binding domain)
that plays an important role in the homologous recom-
bination (HR) repair of damaged DNA in cells [29, 30].
In the exon 10 of BRCA2 gene we have also identified 2
known missense mutations (Table 2). Among these two,
one is p.Asn372His (rs144848) which is a common non-
synonymous polymorphism in exon 10 of the BRCA2
gene [31]. The change from A to C in the rs144848 poly-
morphism results in an asparagine-to-histidine transition
(p.N372H) which may affect BRCA2 structure at resi-
dues 290–453, a region responsible to interact with the
histone acetyl transferase P/CAF prior to transcriptional
activation of target genes [32]. Multiple independent
studies have identified varying degree of association of
rs144848 p.N372H polymorphism in cancer risk, but the
susceptibility to breast cancer is still inconclusive [33–
38]. Another variant (p.Thr598Ala) within exon 10 was
found to have conflicting pathogenicity within literature
[39]. We have identified another novel missense variant
p.Val2151Ile (Table 2) in exon 11 of BRCA2 gene. We
have also identified a known pathogenic mutation
p.Trp2574Ter (Table 2) in the exon 16 of BRCA2 gene.
This variant likely to cause the protein to be abnormally
truncated at the amino acid position 2574. It is located
within the DNA-binding domain (DBD: belongs to
2481–3186 amino acids) of BRCA2 gene that binds sin-
gle-stranded DNA (ssDNA) and double-stranded DNA
(dsDNA). The DBD contains five components: a 190-
amino-acid α-helical domain, three oligonucleotide bind-
ing (OB) folds that are ssDNA-binding modules, and a
tower domain (TD) that protrudes from OB2 and binds
Table 2 List of clinically relevant variants detected within the BRCA1, BRCA2 and ERBB2 genes applying targeted sequencing from
blood derived DNA samples in our breast cancer cohort recruited from Bangladesh
Sample Id Gene name Coordinate [position] (hg19) Mutation Types Significance Exon Nucleotide change Amino acid change
1 BRCA2 32,931,983 Stopgain pathogenic 16 c.7722 G > A p.Trp2574Ter
2 BRCA2 32,906,729 Nonsynonymous VUS 10 c.1114 A > C p.Asn372His
3 BRCA2 32,907,407 Nonsynonymous VUS 10 c.1792A > G p.Thr598Ala
4 BRCA1 41,222,983 Nonsynonymous* Pathogenic 16 c.5011 T > C p.Met1671Val
5 BRCA1 41,245,262 Nonsynonymous VUS 10 c.2286A > T p.Arg762Ser
6 BRCA1 41,243,553 Nonsynonymous VUS 10 c.3995 C > A p.Gly1332Val
7 BRCA2 32,906,916–32,906,923 frameshift deletion * Pathogenic 10 c.1301_1308del AAAGAAAG p.Lys436Phefs*
8 BRCA1 41,246,489 Stopgain pathogenic 10 c.1058G > A p.Trp353Ter
9 BRCA2 32,899,247 frameshift deletion * Pathogenic 4 c.351_352delTC p.Arg118Hisfs*
10 ERBB2 37,880,988 Nonsynonymous* VUS 24 c.2272 G > C p.Val758Leu
11 BRCA2 32,914,943 Nonsynonymous* Pathogenic 11 c.6451 G > A p.Val2151Ile
*defines the novel variants in our cohort
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dsDNA [40]. The helical domains, OB1 and OB2 also as-
sociate with deleted in split-hand/split-foot syndrome
(DSS1), which has been linked to BRCA2 protein
stabilization [40–43]. This variant is pathogenic and was
found in the patients of Hereditary Breast and Ovarian
Cancer syndrome [39].
Out of 10 sequence variants in BRCA1 and BRCA2 gene,
we have found 1 novel missense mutation p.Met1671Val
(Table 2) in exon 16 of BRCA1 gene. This mutation is lo-
cated within the phosphoprotein-binding C-terminal BRCT
domain which is critical for the tumor suppression function
of BRCA1 gene [44]. We have also identified 3 known
mutations in the exon 10 of BRCA1 gene. Among these
mutations, 2 are missense mutations p.Arg762Ser and
p.Gly1332Val (Table 2) and another 1 is stopgain mutation
p.Trp353Ter (Table 2). The missense mutations were previ-
ously identified in patients with breast cancer and heredi-
tary cancer-predisposing syndrome and were defined as
VUS [39, 45]. The stopgain mutation was previously identi-
fied in the patients of hereditary breast and ovarian cancer
syndrome and was defined as pathogenic [39, 45, 46].
We have also identified a novel missense mutation
p.Val758Leu (Table 2) in the exon 24 of ERBB2 gene.
ERBB2 kinase domain mutation occurs in human can-
cers such as gastric, breast, and colorectal cancers, and
suggested that alterations of ERBB2-mediated signaling
pathway by ERBB2 mutations alone or together with K-
RAS mutations may contribute to the development of
human cancers [47].
We also identified four mutations in 3 of the 9 breast
tumor tissue samples, including 22% (2/9) with pathogenic
mutations in TP53 gene, comparable to data from the
International Agency for Research on Cancer (IARC) [48].
The patient carrying this frameshift mutation also has an-
other pathogenic mutation, c.116 G > A in the exon 3 of
BRCA1 gene which was previously identified in the pa-
tients of hereditary breast and ovarian cancer syndrome,
neoplasm of the breast and hereditary cancer-predisposing
syndrome [39, 49]. The majority of the mutations occur in
the hot-spots exons 5, 7 and 8 [50, 51] of TP53 gene.
Mazars et al found that among patients with ovarian can-
cer, all p53 mutations clustered in exons 5 and 7 [52].
Somatic TP53 gene alterations are frequent in most hu-
man cancers, ranging from 5 to 80% depending on the
type, stage, and etiology of tumors [53]. BC tumors also
are impacted by frequent TP53 mutations and based on
the mutation type and location, cancer subtype can be
classified based on treatment and prognosis. Hence, TP53
mutated warrant targeted treatment depending on the
TP53 mutation status [13]. Inherited TP53 mutations pre-
dispose to a wide spectrum of early-onset cancers and are
associated with Li-Fraumeni and Li-Fraumeni-like
syndrome (LFS and LFL), respectively [54]. We also
identified another missense mutation p.Asp820Gly
(Table 1) in the exon 11 of BRCA2 gene that was previ-
ously identified in the patients of familial breast-ovarian
cancer syndrome [39, 55].
Conclusion
In this study, we have designed a cost effective targeted
gene panel to investigate the mutational landscape of 4
high impact breast cancer genes (BRCA1, BRCA2, ERBB2
and TP53) in breast tumor and in blood. This is the first
paper on breast cancer mutation screening on Bangladeshi
Table 3 Descriptive statistics of the breast cancer cohort
Description History of
study cases
(specimen type:
blood)
% History of
study cases
(specimen type:
tissue)
%
Number of
samples
43/52 82.69 9/52 17.31
Age range (years)
30–39 13/43 30.23 3/9 33.33
40–49 16/43 37.21 3/9 33.33
50–70 14/43 32.56 3/9 33.33
Clinical information
Breast Cancer 23/43 53.49 9/9 100.00
Stage I 5/23 21.74 0/9 0.00
Stage II 12/23 52.17 5/9 55.55
Stage III 6/23 26.09 2/9 22.22
Stage
unknown
N/A N/A 2/9 22.22
Grade I 3/23 13.04 – –
Grade II 13/23 56.52 – –
Grade III 6/23 26.09 – –
Grade
unknown
1/23 4.35 9/9 100
Breast lump 11/43 25.58 – –
Breast pain and
secretion
5/43 11.63 – –
No symptoms 4/43 9.30 – –
Family History
Positive 38/43 88.37 2/9 22.22
Negative 5/43 11.63 3/9 33.33
Unknown – – 4/9 44.44
Mutation
found(including
VUS and
Pathogenic)
11/43 25.58 3/9
(1 patient carried 2
mutations. So total
number of mutations
in 3 patients are 4)
33.33
BRCA1(V + P) 4/43 9.30 1/9 33.33
BRCA2(V + P) 6/43 13.95 1/9 33.33
TP53(P) – – 2/9 22.22
ERBB2(V) 1/43 2.32 – –
Note: V:VUS and P: Pathogenic
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population that is ethnically a homogenous population.
We have identified 5 novel mutations that are extremely
rare in other populations, as well as known pathogenic
mutations for breast cancer. The accumulation of more
genomic data will be able to quantitate their true preva-
lence, as well as their association with other disease phe-
notypes. We have also observed clinically relevant
mutation enrichment within BRCA2 genes. Our list of de-
tected variants of unknown significance will also provide
the opportunity to conduct further research to clarify am-
biguous pathogenicity. In recent years, breast cancer be-
coming a major issue in developing countries due to low
survival rate compared to developed countries. The identi-
fication of novel mutations from a homogenous popula-
tion will add great value to breast cancer genetics.
Moreover, this paper will bring broader community
awareness on cancer genetic tests and the implementation
of precision medicine in general for the country.
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Fig. 1 Sequence chromatograms of all novel mutations detected in BRCA1, BRCA2, TP53, and ERBB2 genes. a and b Forward and reverse strands
sequence of pathogenic frameshift insertion mutation c.322dupG in TP53 gene. c and (d) Forward and reverse strands sequence of pathogenic
missense mutation c.5011 T >C in BRCA1 gene. e and f Forward and reverse strands sequence of pathogenic frameshift deletion mutations c.351_352delTC in
BRCA2 gene. g and h Forward and reverse strands sequence of pathogenic frameshift deletion mutationc.1301_1308del AAAGAAAG in BRCA2 gene. i and j
Reverse strand sequence of missense mutation c.6451G>A and c.2272G>Cin BRCA2 and ERBB2 genes respectively
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